Physician profile
Kara E Davis
NPI 1417991449
$1,069.15
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $157.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $367.87 | 2019-2020 | |
| Amgen INC. | $131.83 | 2019-2020 | |
| Novo Nordisk INC | $131.38 | 2019-2020 | |
| Lilly USA, LLC | $112.87 | 2019-2020 | |
| Pfizer INC. | $97.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $61.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.32 | 2019 | |
| Merck Sharp & Dohme LLC | $30.89 | 2019 | |
| Vyera Pharmaceuticals, LLC | $16.24 | 2019 | |
| Medtronic Minimed, INC. | $14.37 | 2019 | |
| Horizon Therapeutics Plc | $11.65 | 2019 |
Research and ownership
$747.80 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.